Citations

Clear

813 citation(s) found for "He, Helen".

Phosphorylation of the Par-1 polarity kinase by protein kinase D regulates 14-3-3 binding and membrane association
Watkins, Janis L., Lewandowski, Katherine T., Meek, Sarah , Störz, Peter , Toker, Alex , Piwnica‐Worms, Helen

Mayo Clinic

Proceedings of the National Academy of Sciences | November 14, 2008 | Volume: 105 | Issue: 47 | Pages: 18378-18383

10.1073/pnas.0809661105 | PMID 19011111 Get It

The Par-1 protein kinases are conserved from yeast to humans, where they function as key polarity determinants. The mammalian Par-1 family is comprised of 4 members (Par-1a, -b, -c, and -d). Previously, we demonstrated that atypical protein kinase C (aPKC) phosphorylates the Par-1 kinases on a conserved threonine residue (T595) to regulate localization and kinase activity. Here, we demonstrate that Par-1b is also regulated by another arm of the PKC pathway, one that involves novel PKCs (nPKC) and protein kinase D. Treatment of cells with the PKC activator phorbol-12-myristate-13-acetate (PMA) potently stimulated phosphorylation of Par-1b on serine 400 (S400), a residue that is conserved in all 4 mammalian Par-1 kinases as well as the fly ortholog. We demonstrate that PMA stimulates nPKC to activate PKD, which in turn directly phosphorylates Par-1b on S400 to positively regulate 14-3-3 binding and to negatively regulate membrane association. Thus, 2 arms of the PKC pathway regulate interactions between Par-1b and 14-3-3 proteins: one involving aPKC and the other nPKC/PKD.
P3‐244: Insulin degrading enzyme and the risk of late‐onset Alzheimer's disease: A large replication study in a European population
Carrasquillo, Minerva M. , Brown, Kristelle, Kalsheker, Noor , Craig, David , Passmore, Peter , Koelsch, Heike, Warden, Donald, Smith, David A. , Younkin, Steven G., Morgan, Kevin , Carrasquillo, Minerva M. , Belbin, Olivia , McGuinness, Bernadette , Heun, Reinhard , Kehoe, Patrick G. , Mann, David , Beaumont, Helen , Holmes, Clive

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_18 | Pages: No page available

10.1016/j.jalz.2008.05.1811 Get It

Computed tomography imaging of the paranasal sinuses: Direct versus reformatted coronal images
Pletcher, Steven D. , Hoxworth, Joseph M. , Goldberg, Andrew N. , Murr, Andrew H. , Glastonbury, Christine M. , Hoxworth, Joseph M

Mayo Clinic

Otolaryngology–Head and Neck Surgery | June 4, 2008 | Volume: 138 | Issue: 6 | Pages: 710-714

10.1016/j.otohns.2008.03.001 | PMID 18503840 Get It

ObjectiveTo evaluate the image quality of coronal reformatted CT images compared with direct coronal CT images.Study DesignCross‐sectional.Subjects and MethodsPatients who underwent paranasal sinus CT scans using both direct coronal images (DC) and axially acquired images with coronal reconstructions (CR) were consecutively enrolled. Two reconstruction groups were evaluated: group CR1 with 1‐mm axial collimation and group CR2 with 0.625‐mm axial collimation. Scans were presented in a randomized, blinded fashion to two sinus surgeons and a neuroradiologist.ResultsWhen compared with CR1, DC images had higher image quality for each of five key anatomic landmarks (P <. 0001). DC images were more likely to be adequate preoperative imaging (P <. 0001). When compared with CR2, improved DC image quality was noted in the majority of key anatomic landmarks. No difference was noted in the “adequacy rating” between the DC and CR2 (0.625 mm) protocols.ConclusionThe 0.625‐mm reformatted images were judged to be adequate preoperative imaging. The additional information provided by multiple‐image planes make reformatted 0.625‐mm axial images an acceptable approach.
Urology Resident Training With an Unexpected Patient Death Scenario: Experiential Learning With High Fidelity Simulation
Gettman, Matthew T., Karnes, R. Jeffrey, Arnold, Jacqueline J., Klipfel, Janee M., Vierstraete, Helen T., Leibovich, Bradley C. , Johnson, Mary E. , Johnson, Daniel R.

Mayo Clinic

Journal of Urology | May 22, 2008 | Volume: 180 | Issue: 1 | Pages: 283-288

10.1016/j.juro.2008.03.042 | PMID 18499174 Get It

Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study
Bender, Julia Glade , Adamson, Peter C. , Xu, Lu , Baruchel, Sylvain , Kerbel, Robert S. , Cooney-Qualter, Erin, Stempak, Diana, Chen, Helen X., Nelson, Marvin D. , Krailo, Mark , Ingle, Ashish M., Blaney, Susan M. , Kandel, Jessica J. , Reid, Joel M. , Shaked, Yuval , Yamashiro, Darrell J. , Glade-Bender, Julia

Mayo Clinic

Journal of Clinical Oncology | January 17, 2008 | Volume: 26 | Issue: 3 | Pages: 399-405

10.1200/jco.2007.11.9230 | PMID 18202416 Get It

Purpose We conducted a pediatric phase I trial of the vascular endothelial growth factor (VEGF)–neutralizing antibody bevacizumab (BV). Primary aims included estimating the maximum-tolerated dose (MTD) and determining the dose-limiting toxicities (DLTs), pharmacokinetics, and biologic effects of BV in children with cancer. Patients and Methods BV (5, 10, 15 mg/kg) was administered intravenously every 2 weeks in 28-day courses to children with refractory solid tumors. Results Twenty-one patients enrolled, 20 (median age, 13 years) were eligible, and 18 completed one course and were fully assessable for toxicity. A total of 67 courses were administered (median, three courses per patient; range, one to 16 courses). Treatment was well tolerated with no DLTs observed. Non-DLTs included infusional reaction, rash, mucositis, proteinuria, and lymphopenia. Increases in systolic and diastolic blood pressure not meeting Common Terminology Criteria for Adverse Events (CTCAEv3) pediatric-specific criteria for hypertension were observed. There was no hemorrhage or thrombosis. Growth perturbation was not detected in a limited sample over the first course. The serum exposure to BV as measured by area under the concentration-time curve (AUC) seemed to increase in proportion to dose. The median clearance of BV was 4.1 mL/d/kg (range, 3.1 to 15.5 mL/d/kg), and the median half-life was 11.8 days (range, 4.4 to 14.6 days). No objective responses were observed. Exploratory analyses on circulating endothelial mobilization and viability are consistent with the available adult data. Conclusion BV is well tolerated in children. Phase II pediatric studies of BV in combination with chemotherapy in dosing schedules similar to adults are planned.
Anastrozole Increases Predicted Adult Height of Short Adolescent Males Treated with Growth Hormone: A Randomized, Placebo-Controlled, Multicenter Trial for One to Three Years
Mauras, Nelly , Pijem, Lilliam Gonzalez de, Hsiang, Helen Y., Desrosiers, Paul, Rapaport, Robert , Schwartz, I. David, Klein, Karen O. , Miyamoto, Anna, Bishop, Kim, Singh, Ravinder J.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 28, 2007 | Volume: 93 | Issue: 3 | Pages: 823-831

10.1210/jc.2007-1559 | PMID 18165285 Get It

Abstract Context: The process of epiphyseal fusion during puberty is regulated by estrogen, even in males. Objective: Our objective was to investigate whether anastrozole, a potent aromatase inhibitor, could delay bone age acceleration and increase predicted adult height in adolescent boys with GH deficiency. Methods: Fifty-two adolescent males with GH deficiency treated with GH were randomized to cotreatment with anastrozole or placebo daily for up to 36 months. Results: Fifty subjects completed 12 months, 41 completed 24 months, and 28 completed 36 months. Linear growth was comparable between groups; however, there was a significantly slower increase in bone age advancement from baseline in the anastrozole group vs. placebo group after 2 yr (+1.8 ± 0.1 vs. +2.7 ± 0.1 yr, P &lt; 0.0001) and after 3 yr (+2.5 ± 0.2 vs. +4.1 ± 0.1 yr, P &lt; 0.0001). This resulted in a net increase in predicted adult height of +4.5 ± 1.2 cm in the anastrozole group at 24 months and +6.7 ± 1.4 cm at 36 months as compared with a 1-cm gain at both time points in the placebo group. Estradiol and estrone concentrations increased less in the anastrozole group compared with placebo group. All boys on the aromatase inhibitor had normal tempo of virilization. Safety data, including glucose, and plasma lipid concentrations were comparable between groups. Conclusions: Anastrozole increases adult height potential of adolescent boys on GH therapy while maintaining normal pubertal progression after 2–3 yr. This treatment offers an alternative in promoting growth in GH-deficient boys in puberty. Long-term follow up is needed to elucidate fully the safety and efficacy of this approach.
Effect of Insulin Deprivation on Muscle Mitochondrial ATP Production and Gene Transcript Levels in Type 1 Diabetic Subjects
Karakelides, Helen, Asmann, Yan W. , Bigelow, Maureen L., Short, Kevin R. , Coenen-Schimke, Jill M., Kahl, Jane, Dhatariya, Ketan , Mukhopadhyay, Debabrata , Nair, K. Sreekumaran

Mayo Clinic

Diabetes | September 5, 2007 | Volume: 56 | Issue: 11 | Pages: 2683-2689

10.2337/db07-0378 | PMID 17660267 Get It

OBJECTIVE—Muscle mitochondrial dysfunction occurs in many insulin-resistant states, such as type 2 diabetes, prompting a hypothesis that mitochondrial dysfunction may cause insulin resistance. We determined the impact of insulin deficiency on muscle mitochondrial ATP production by temporarily depriving type 1 diabetic patients of insulin treatment. RESEARCH DESIGN AND METHODS—We withdrew insulin for 8.6 ± 0.6 h in nine C-peptide–negative type 1 diabetic subjects and measured muscle mitochondrial ATP production and gene transcript levels (gene array and real-time quantitative PCR) and compared with insulin-treated state. We also measured oxygen consumption (indirect calorimetry); plasma levels of glucagon, bicarbonate, and other substrates; and urinary nitrogen. RESULTS—Withdrawal of insulin resulted in increased plasma glucose, branched chain amino acids, nonesterified fatty acids, β-hydroxybutyrate, and urinary nitrogen but no change in bicarbonate. Insulin deprivation decreased muscle mitochondrial ATP production rate (MAPR) despite an increase in whole-body oxygen consumption and altered expression of many muscle mitochondrial gene transcripts. Transcript levels of genes involved in oxidative phosphorylation were decreased, whereas those involved in vascular endothelial growth factor (VEGF) signaling, inflammation, cytoskeleton signaling, and integrin signaling pathways were increased. CONCLUSIONS—Insulin deficiency and associated metabolic changes reduce muscle MAPR and expression of oxidative phosphorylation genes in type 1 diabetes despite an increase in whole-body oxygen consumption. Increase in transcript levels of genes involved in VEGF, inflammation, cytoskeleton, and integrin signaling pathways suggest that vascular factors and cell proliferation that may interact with mitochondrial changes occurred.
Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups
O’Dwyer, Peter J. , Haller, Daniel G. , Tepper, Joel E. , Ahnen, Dennis J. , Benson, Al B. , Rothenberg, Mace L., Petrelli, Nicholas J. , Lenz, Heinz‐Joseph, Diasio, Robert B. , Dubois, Raymond, Sargent, Daniel J. , Sloan, Jeff A. , Johnson, C. Daniel, Comis, Robert L., Eckhardt, Sabine , Hamilton, Stanley R. , O’Connell, Michael J. , Sargent, Daniel J

Mayo Clinic

Journal of Clinical Oncology | May 30, 2007 | Volume: 25 | Issue: 16 | Pages: 2313-2321

10.1200/jco.2006.08.6900 | PMID 17538178 Get It

Emerging technologies have greatly expanded our ability to detect, characterize, and treat colorectal cancer. The Coalition of Cancer Cooperative Groups convened a multidisciplinary panel, the Scientific Leadership Council in GI cancer, to discuss and advise on the priorities and opportunities to advance current and future approaches into the clinical arena to impact most rapidly the morbidity and mortality from this disease. The Council's recommendations for research priorities are the result of engagement of community and academic oncologists, patient advocacy groups, and other stakeholders including the pharmaceutical industry and governmental agencies. We detail some key prospects for investigation in the areas of colon cancer detection, prevention, and surgical and medical management. Many are in early or definitive clinical trials, and a focus on rapid accrual is urged. The implementation of biology-directed laboratory investigations, both in association with ongoing clinical trials and as a separate developmental strategy for targeted therapies, is supported as the route to individualized therapy.
Intensive Dose-Dense Compared With High-Dose Adjuvant Chemotherapy for High-Risk Operable Breast Cancer: Southwest Oncology Group/Intergroup Study 9623
Bearman, Scott I., Lew, Danika L., Hudis, Clifford A. , Wolff, Antonio C. , Chew, Helen K. , Livingston, Robert B., Martino, Silvana, Moore, Halle C. F. , Green, Stephanie , Gralow, Julie R. , Barlow, William E. , Ingle, James N. , Elias, Anthony , Wolff, Antonio C

Mayo Clinic

Journal of Clinical Oncology | April 3, 2007 | Volume: 25 | Issue: 13 | Pages: 1677-1682

10.1200/jco.2006.08.9383 | PMID 17404368 Get It

Purpose Southwest Oncology Group (SWOG)/Intergroup study 9623 was undertaken to compare treatment with an anthracycline-based adjuvant chemotherapy regimen followed by high-dose chemotherapy (HDC) with autologous hematopoietic progenitor cell support (AHPCS) with a modern dose-dense dose-escalated (nonstandard) regimen including both an anthracycline and a taxane. Patients and Methods Participants in this phase III randomized study had operable breast cancer involving four or more axillary lymph nodes and had completed mastectomy or breast-conserving surgery. Patients were randomly assigned to receive four cycles of doxorubicin and cyclophosphamide followed by HDC with AHPCS or to receive sequential dose-dense and dose-escalated chemotherapy with doxorubicin, paclitaxel, and cyclophosphamide. The primary end point of this study was disease-free survival (DFS). Results Among 536 eligible patients, there was no significant difference between the two arms for DFS or overall survival (OS). Estimated five-year DFS was 80% (95% CI, 76% to 85%) for dose-dense therapy and 75% (95% CI, 69% to 80%) for transplantation. Estimated 5-year OS was 88% (95% CI, 84% to 92%) for dose-dense therapy and 84% (95% CI, 79% to 88%) for transplantation. Conclusion There is no evidence that transplantation was superior to dose-dense dose-escalated therapy. Transplantation was associated with an increase in toxicity and a possibly inferior outcome, although the hazard ratios were not significantly different from 1.
Synthesis of Novel Caspase Inhibitors for Characterization of the Active Caspase Proteome in Vitro and in Vivo
Henzing, Alexander J., Dodson, Helen , Kaufmann, Scott H. , Baxter, Robert L., Earnshaw, William C. , Reid, Joel M. , Kaufmann, Scott H

Mayo Clinic

Journal of Medicinal Chemistry | December 7, 2006 | Volume: 49 | Issue: 26 | Pages: 7636-7645

10.1021/jm060385h | PMID 17181147 Get It